JNJ – Johnson & Johnson
Johnson & JohnsonJNJ
$147.03Name : Johnson & Johnson
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $353,992,376,320.00
EPSttm : 6.04
Johnson & Johnson
$147.03
0.50%$0.74Float Short %
0.68
Margin Of Safety %
24
Put/Call OI Ratio
0.57
EPS Next Q Diff
0.22
EPS Last/This Y
-3.92
EPS This/Next Y
0.66
Price
147.07
Target Price
172.59
Analyst Recom
2.23
Performance Q
-10.5
Relative Volume
1.36
Beta
0.51
Ticker: JNJ
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | JNJ | 143.56 | 0.62 | 1.22 | 385148 |
| 2024-12-20 | JNJ | 144.45 | 0.61 | 0.65 | 389513 |
| 2024-12-23 | JNJ | 145.23 | 0.68 | 0.45 | 337426 |
| 2024-12-24 | JNJ | 145.79 | 0.62 | 0.54 | 359822 |
| 2024-12-26 | JNJ | 145.54 | 0.61 | 0.85 | 367514 |
| 2024-12-27 | JNJ | 145.09 | 0.60 | 0.79 | 381806 |
| 2024-12-30 | JNJ | 143.32 | 0.63 | 0.63 | 368271 |
| 2024-12-31 | JNJ | 144.63 | 0.63 | 0.70 | 376430 |
| 2025-01-02 | JNJ | 144 | 0.64 | 2.23 | 384688 |
| 2025-01-03 | JNJ | 144.19 | 0.65 | 0.77 | 390052 |
| 2025-01-06 | JNJ | 143.64 | 0.65 | 0.56 | 384620 |
| 2025-01-07 | JNJ | 146.23 | 0.63 | 0.57 | 401367 |
| 2025-01-08 | JNJ | 142.25 | 0.62 | 1.77 | 411183 |
| 2025-01-09 | JNJ | 142.27 | 0.62 | 1.69 | 411183 |
| 2025-01-10 | JNJ | 142.06 | 0.61 | 0.69 | 419530 |
| 2025-01-13 | JNJ | 144.49 | 0.61 | 0.58 | 408913 |
| 2025-01-14 | JNJ | 144.76 | 0.60 | 0.60 | 425235 |
| 2025-01-15 | JNJ | 144.93 | 0.59 | 0.41 | 433786 |
| 2025-01-16 | JNJ | 147.8 | 0.57 | 1.03 | 442201 |
| 2025-01-17 | JNJ | 147.06 | 0.57 | 0.39 | 446965 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | JNJ | 143.57 | -11.0 | 10614.0 | 9.96 |
| 2024-12-20 | JNJ | 144.45 | -11.0 | 11011.7 | 9.96 |
| 2024-12-23 | JNJ | 145.27 | -11.0 | 10997.1 | 9.96 |
| 2024-12-24 | JNJ | 145.85 | -11.0 | 10953.9 | 9.96 |
| 2024-12-26 | JNJ | 145.58 | -11.0 | 10790.3 | 9.96 |
| 2024-12-27 | JNJ | 145.08 | -11.0 | 10745.9 | 9.96 |
| 2024-12-30 | JNJ | 143.33 | -11.0 | 10510.2 | 9.96 |
| 2024-12-31 | JNJ | 144.61 | -11.0 | 11090.1 | 9.96 |
| 2025-01-02 | JNJ | 144.01 | -11.0 | 10724.2 | 9.96 |
| 2025-01-03 | JNJ | 144.19 | -11.0 | 10875.2 | 9.96 |
| 2025-01-06 | JNJ | 143.66 | -11.0 | 10739.4 | 9.96 |
| 2025-01-07 | JNJ | 146.22 | -11.0 | 11340.9 | 9.96 |
| 2025-01-08 | JNJ | 142.27 | -11.0 | 10083.7 | 9.96 |
| 2025-01-09 | JNJ | 142.27 | -11.0 | 10842.2 | 9.96 |
| 2025-01-10 | JNJ | 142.04 | -11.0 | 10797.0 | 9.96 |
| 2025-01-13 | JNJ | 144.46 | -11.0 | 10212.5 | 9.96 |
| 2025-01-14 | JNJ | 144.74 | -11.0 | 9808.8 | 9.96 |
| 2025-01-15 | JNJ | 144.93 | -11.0 | 9791.1 | 9.96 |
| 2025-01-16 | JNJ | 147.77 | -11.0 | 10278.4 | 9.96 |
| 2025-01-17 | JNJ | 147.07 | -11.0 | 9629.7 | 9.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | JNJ | -0.16 | 0.66 | 0.77 |
| 2024-12-20 | JNJ | -0.16 | 0.66 | 0.77 |
| 2024-12-23 | JNJ | -0.16 | 0.63 | 0.77 |
| 2024-12-24 | JNJ | -0.16 | 0.63 | 0.77 |
| 2024-12-26 | JNJ | -0.16 | 0.63 | 0.73 |
| 2024-12-27 | JNJ | -0.16 | 0.63 | 0.73 |
| 2024-12-30 | JNJ | -0.16 | 0.57 | 0.73 |
| 2024-12-31 | JNJ | -0.16 | 0.57 | 0.73 |
| 2025-01-02 | JNJ | -0.16 | 0.57 | 0.73 |
| 2025-01-03 | JNJ | -0.16 | 0.57 | 0.73 |
| 2025-01-06 | JNJ | -0.16 | 0.56 | 0.73 |
| 2025-01-07 | JNJ | -0.16 | 0.56 | 0.73 |
| 2025-01-08 | JNJ | -0.16 | 0.56 | 0.73 |
| 2025-01-09 | JNJ | -0.16 | 0.56 | 0.73 |
| 2025-01-10 | JNJ | -0.16 | 0.56 | 0.73 |
| 2025-01-13 | JNJ | -0.16 | 0.73 | 0.68 |
| 2025-01-14 | JNJ | -0.16 | 0.73 | 0.68 |
| 2025-01-15 | JNJ | -0.16 | 0.73 | 0.68 |
| 2025-01-16 | JNJ | -0.16 | 0.73 | 0.68 |
| 2025-01-17 | JNJ | -0.16 | 0.73 | 0.68 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.42
Avg. EPS Est. Current Quarter
2.04
Avg. EPS Est. Next Quarter
2.64
Insider Transactions
-0.16
Institutional Transactions
0.73
Beta
0.51
Average Sales Estimate Current Quarter
22455
Average Sales Estimate Next Quarter
22032
Fair Value
182.05
Quality Score
96
Growth Score
79
Sentiment Score
79
Actual DrawDown %
21.2
Max Drawdown 5-Year %
-27.4
Target Price
172.59
P/E
24.3
Forward P/E
13.91
PEG
3.92
P/S
4.04
P/B
5.04
P/Free Cash Flow
17.06
EPS
6.05
Average EPS Est. Cur. Y
9.96
EPS Next Y. (Est.)
10.62
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
16.75
Relative Volume
1.36
Return on Equity vs Sector %
1.9
Return on Equity vs Industry %
-5.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
9629.7
Johnson & JohnsonSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 131900
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
stock quote shares JNJ – Johnson & Johnson Stock Price stock today
news today JNJ – Johnson & Johnson stock forecast ,stock prediction 2023 2024 2025
marketwatch JNJ – Johnson & Johnson yahoo finance google finance
stock history JNJ – Johnson & Johnson invest stock market
stock prices JNJ premarket after hours
ticker JNJ fair value insiders trading